American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 415-424 , March 2008

A Longitudinal Study of Risk Factors for Incident Albuminuria in Diabetic American Indians: The Strong Heart Study

  • Jiaqiong Xu, PhD

      Affiliations

    • Center for American Indian Health Research, University of Oklahoma Health Sciences Center, Oklahoma City, OK
    • Corresponding Author InformationAddress correspondence to Jiaqiong Xu, PhD, Center for Biostatistics, The Methodist Hospital Research Institute, 6565 Fannin St MGJ6, Houston, TX 73030.
    • ,
  • Elisa T. Lee, PhD

      Affiliations

    • Center for American Indian Health Research, University of Oklahoma Health Sciences Center, Oklahoma City, OK
    • ,
  • Richard B. Devereux, MD

      Affiliations

    • Weill Cornell Medical College, New York, NY
    • ,
  • Jason G. Umans, MD, PhD

      Affiliations

    • MedStar Research Institute, Hyattsville, MD
    • ,
  • Jonathan N. Bella, MD

      Affiliations

    • Bronx-Lebanon Hospital Center and Albert Einstein College of Medicine, Bronx, NY
    • ,
  • Nawar M. Shara, PhD

      Affiliations

    • MedStar Research Institute, Hyattsville, MD
    • ,
  • Jeunliang Yeh, PhD

      Affiliations

    • Center for American Indian Health Research, University of Oklahoma Health Sciences Center, Oklahoma City, OK
    • ,
  • Richard R. Fabsitz, PhD

      Affiliations

    • National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
    • ,
  • Barbara V. Howard, PhD

      Affiliations

    • MedStar Research Institute, Hyattsville, MD

Received 5 June 2007 ,Accepted 14 November 2007.

References 

  1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–360
  2. Arun CS, Stoddart J, Mackin P, MacLeod JM, New JP, Marshall SM. Significance of microalbuminuria in long-duration type 1 diabetes. Diabetes Care. 2003;26:2144–2149
  3. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus (A systematic overview of the literature). Arch Intern Med. 1997;157:1413–1418
  4. Niskanen LK, Penttila I, Parviainen M, Uusitupa MI. Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care. 1996;19:486–493
  5. Xu J, Lee ET, Best LG, et al. Association of albuminuria with all-cause and cardiovascular disease mortality in diabetes: The Strong Heart Study. Br J Diabetes Vasc Dis. 2005;5:334–340
  6. Jager A, Kostense PJ, Ruhe HG, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:617–624
  7. Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H. Microalbuminuria and all-cause mortality in treated hypertensive individuals: Does sex matter? The Nord-Trondelag Health Study (HUNT), Norway. Circulation. 2003;108:2783–2789
  8. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–1782
  9. Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol. 2004;33:189–198
  10. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Bennett PH. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care. 1995;18:182–187
  11. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU. Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care. 1998;21:530–534
  12. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study. BMJ. 1997;314:783–788
  13. Murussi M, Baglio P, Gross JL, Silveiro SP. Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: A 9-year follow-up study. Diabetes Care. 2002;25:1101–1103
  14. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes. 2006;55:1832–1839
  15. Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study (A study of cardiovascular disease in American Indians: Design and methods). Am J Epidemiol. 1990;132:1141–1155
  16. Lee ET, Cowan LD, Welty TK, et al. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-74 years, 1984-1988 (The Strong Heart Study). Am J Epidemiol. 1998;147:995–1008
  17. Lee ET, Welty TK, Cowan LD, et al. Incidence of diabetes in American Indians of three geographic areas: The Strong Heart Study. Diabetes Care. 2002;25:49–54
  18. Robbins DC, Knowler WC, Lee ET, et al. Regional differences in albuminuria among American Indians: An epidemic of renal disease. Kidney Int. 1996;49:557–563
  19. Hayslett JA, Eichner JE, Yeh JL, et al. Hypertension treatment patterns in American Indians: The Strong Heart Study. Am J Hypertens. 2001;14:950–956
  20. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197
  21. Chasson A, Grady H, Stanley M. Determination of creatinine by means of automatic chemical analysis. Tech Bull Regist Med Tech. 1957;30:207–212
  22. Vasquez B, Flock EV, Savage PJ, et al. Sustained reduction of proteinuria in type 2 (non-insulin-dependent) diabetes following diet-induced reduction of hyperglycaemia. Diabetologia. 1984;26:127–133
  23. Diggle P, Heagerty P, Liang K, Zeger S. Analysis of Longitudinal Data. Oxford, UK: Oxford University; 2002;
  24. Xu J, Knowler WC, Devereux RB, et al. Albuminuria within the “normal” range and risk of cardiovascular disease and death in American Indians: The Strong Heart Study. Am J Kidney Dis. 2007;49:208–216
  25. Horton NJ, Bebchuk JD, Jones CL, et al. Goodness-of-fit for GEE: An example with mental health service utilization. Stat Med. 1999;18:213–222
  26. Parving HH, Hommel E. Prognosis in diabetic nephropathy. BMJ. 1989;299:230–233
  27. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia. 1983;25:496–501
  28. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med. 1985;78:785–794
  29. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426
  30. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Intern Med. 2003;139:901–906
  31. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation. 2005;112:969–975
  32. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998–1004
  33. Forsblom CM, Groop PH, Ekstrand A, et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care. 1998;21:1932–1938
  34. Klein R, Klein BE, Moss SE. Incidence of gross proteinuria in older-onset diabetes (A population-based perspective). Diabetes. 1993;42:381–389
  35. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 2000;57:590–600
  36. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878
  37. Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens. 1996;10:185–192
  38. Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. BMJ. 1992;305:981–985
  39. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients (North-East Italy Microalbuminuria Study Group). Am J Hypertens. 1995;8:876–883
  40. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):S79–S83
  41. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2):S1–S266(suppl 1)

 Originally published online as doi:10.1053/j.ajkd.2007.11.010 on January 21, 2008.

PII: S0272-6386(07)01563-6

doi: 10.1053/j.ajkd.2007.11.010

American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 415-424 , March 2008

Article Tools

* Image Usage & Resolution